Pfizer and BioNTech got agreement with United Kingdom for 30m doses of vaccine candidate
Topics: PFIZER BIONTECH
Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses.
The BNT162 program is based on BioNTech’s proprietary mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities.
The BNT162 vaccine candidates are undergoing clinical studies and are not currently approved for distribution anywhere in the world.
BioNTech is the market authorization holder worldwide and will hold all trademarks for the potential product.
Both collaborators are committed to developing these novel vaccines with pre clinical and clinical data at the forefront of all their decision making. ■